ReutersOctober 23, 2026Industry
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Reported by Reuters. Read the original →
What the story says
J.P. Morgan reports that the growing use of GLP-1 in China, India, and Brazil could lead to a market valued at $22 billion by 2035.
Summarised by a model from Reuters's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
GLP-1 and incretin therapiesclass
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.